In this phase II, open‐label, single‐arm study of cabozantinib of Japanese patients with advanced RCC and prior systemic therapy with VEGFR‐TKIs, ORR was 20.0% (90% CI 9.8–34.3%). The gene discussed is KDR; the disease is renal cell carcinoma.